medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2020, Number 3

<< Back Next >>

Rev Latin Infect Pediatr 2020; 33 (3)

Isoniazid-resistant Mycobacterium tuberculosis: the treatment dilemma

Castillo-Bejarano JI, Guerrero-Márquez NA, Vaquera-Aparicio DN, Mascareñas-de los Santos AH, Cárdenas-del Castillo BG, Garza-Bulnes R

Language: Spanish
References: 15
Page: 138-142
PDF size: 195.23 Kb.


ABSTRACT

Drug resistant tuberculosis is a global public health problem. Although resistance to isoniazid has a prevalence of 5.7% in the region of the Americas, the information available on the management of these cases in children is scarce, so the scheme and duration of treatment is a dilemma. We describe a case with a delayed diagnosis of isoniazid monoresistance and a review of the literature.


REFERENCES

  1. World Health Organization. Global Tuberculosis Report 2019. Geneva, Switzerland: World Health Organization; 2019.

  2. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017; 17 (2): 223-234.

  3. Stagg HR, Harris RJ, Hatherell HA et al. What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax. 2016; 71 (10): 940-949.

  4. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization; 2018.

  5. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, Switzerland: World Health Organization; 2019.

  6. Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2018; 22 (5): S3-S6.

  7. Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016; 16 (10): 1193-1201.

  8. Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant tuberculosis in children: a systematic review. Pediatr Infect Dis J. 2013; 32 (5): e217-e226.

  9. Yuen CM, Jenkins HE, Rodriguez CA, Keshavjee S, Becerra MC. Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics. 2015; 136 (1): e50-e59.

  10. World Health Organization. Guidance for national tuberculosis programs on the management of tuberculosis in children. 2nd ed. Geneva, Switzerland: World Health Organization; 2014.

  11. Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016; 20:1099-1104.

  12. Abate D, Tedla Y, Meressa D, Ameni G. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuber Lung Dis. 2014; 18 (8): 946-951.

  13. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol. 2011; 49 (7): 2540-2545.

  14. Bates M. The development, evaluation and performance of molecular diagnostics for detection of Mycobacterium tuberculosis. Expert Rev Mol Diagn. 2016; 16 (3): 307-322.

  15. Fregonese F, Ahuja SD, Akkerman OW et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018; 6 (4): 265-275.




2020     |     www.medigraphic.com